Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed strength.

Sanofi agreed to buy Blueprint Medicines for up to $9.5 billion, the French drugmaker’s biggest move yet to replenish its drug pipeline since it sold a controlling stake in its consumer ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, in a deal designed to expand the buyer’s rare immunological disease portfolio with an FDA-approved ...

Blueprint Medicines (BPMC) shares are soaring after Sanofi (SNY) agreed to acquire the company for up to $9.5 billion. Boeing (BA) shares were upgrade to Buy from Neutral at Bank of Bank of America.

A phase 3 trial of Cogent Biosciences’ bezuclastinib has hit its primary endpoint, teeing the biotech up to seek FDA approval ...

Blueprint Medicines (NASDAQ:BPMC) is gearing up to announce its quarterly earnings on Thursday, 2025-05-01. Here's a quick overview of what investors should know before the release. Analysts are ...

Sanofi SAN-1.02%decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04%increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest move ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...

PARIS and CAMBRIDGE, Mass., June 2, 2025 /PRNewswire/ -- Sanofi and Blueprint Medicines Corporation (Blueprint), a US-based, publicly traded biopharmaceutical company specializing in systemic ...